Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.360
-0.110 (-7.48%)
Mar 31, 2025, 1:37 PM EDT - Market open

Pliant Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Revenue
-1.589.697.5741.82
Upgrade
Revenue Growth (YoY)
--83.69%27.91%-81.89%-26.70%
Upgrade
Gross Profit
-1.589.697.5741.82
Upgrade
Selling, General & Admin
59.0657.9339.9527.5617.27
Upgrade
Research & Development
169.31127.896.9477.5566.19
Upgrade
Operating Expenses
228.37185.73136.89105.1183.46
Upgrade
Operating Income
-228.37-184.15-127.2-97.54-41.65
Upgrade
Interest Expense
-3.02-1.27-0.79--
Upgrade
Interest & Investment Income
21.0924.084.670.270.11
Upgrade
Pretax Income
-210.3-161.34-123.32-97.26-41.53
Upgrade
Net Income
-210.3-161.34-123.32-97.26-41.53
Upgrade
Net Income to Common
-210.3-161.34-123.32-97.26-41.53
Upgrade
Shares Outstanding (Basic)
6159423621
Upgrade
Shares Outstanding (Diluted)
6159423621
Upgrade
Shares Change (YoY)
3.10%39.75%17.21%67.94%1214.82%
Upgrade
EPS (Basic)
-3.47-2.75-2.94-2.71-1.95
Upgrade
EPS (Diluted)
-3.47-2.75-2.94-2.71-1.95
Upgrade
Free Cash Flow
-159.35-117.28-96.39-77.4-38.8
Upgrade
Free Cash Flow Per Share
-2.63-2.00-2.29-2.16-1.82
Upgrade
Gross Margin
-100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
--11654.75%-1313.37%-1288.10%-99.59%
Upgrade
Profit Margin
--10211.14%-1273.32%-1284.51%-99.32%
Upgrade
Free Cash Flow Margin
--7422.91%-995.26%-1022.13%-92.79%
Upgrade
EBITDA
-226.24-182.3-125.38-96-40.34
Upgrade
EBITDA Margin
-----96.46%
Upgrade
D&A For EBITDA
2.131.841.821.541.31
Upgrade
EBIT
-228.37-184.15-127.2-97.54-41.65
Upgrade
EBIT Margin
-----99.59%
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q